September 20, 2006 -- Connetics won FDA approval of Verdeso Foam, a therapy for mild to moderate dermatitis; Genta sold 20 million shares at approximately $.80 each to raise $16 million; Amgen licensed monoclonal antibody IP from Yeda Research; GlaxoSmithKline and Pozen released positive data about migraine drug Trexima; Avant is quarreling with GlaxoSmithKline over royalties being paid on Rotarix rotavirus vaccine; Isis Pharma won a patent for its bacterial identification product; Progenics and Wyeth moved their therapy for post-operative ileus into Phase III trials; and Immtech announced the Gates Foundation gave $21.3 million to develop a drug for African sleeping sickness. The Centient Biotech 200™ jumped 24.5 points to end the day at 3743.75, a gain of .66%. More details...
